Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$263.39B | -61.7x | -1.65 | HK$158.90 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.1% Upside | Upgrade to Pro+ | |
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$202.97B | 17.2x | -0.91 | HK$74.95 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.5% Upside | Upgrade to Pro+ | |
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$108.02B | 27.3x | 19.01 | HK$26.65 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.4% Upside | Upgrade to Pro+ | |
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$86.48B | -133.5x | 1.19 | HK$94.15 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.8% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$79.85B | -223x | -4.62 | HK$343 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.9% Downside | Upgrade to Pro+ | |
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$49.03B | 134.6x | -1.64 | HK$40.50 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.1% Downside | Upgrade to Pro+ | |
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$48.50B | 23.7x | 0.85 | HK$16.72 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.2% Upside | Upgrade to Pro+ | |
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$36.52B | -71.7x | -0.02 | HK$16.86 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.3% Upside | Upgrade to Pro+ | |
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$34.06B | -16.5x | -2.08 | HK$48 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -29.3% Downside | Upgrade to Pro+ | |
Innocare | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$27.53B | -57.9x | -1.45 | HK$12.96 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.4% Downside | Upgrade to Pro+ | |
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$20.36B | -30.1x | -0.76 | HK$59.45 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2% Downside | Upgrade to Pro+ | |
Joinn Laboratories China Co | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$15.64B | 38.2x | 0.05 | HK$15.06 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -36.8% Downside | Upgrade to Pro+ | |
Keymed Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$13.41B | -22.9x | 0.54 | HK$46.95 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.6% Upside | Upgrade to Pro+ | |
CARsgen Therapeutics Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$11.01B | -9.9x | 1.76 | HK$21.60 | 8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -50.4% Downside | Upgrade to Pro+ | |
TYK Medicines | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$8.42B | -19x | -1.46 | HK$22.45 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.4% Upside | Upgrade to Pro+ | |
Alphamab | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$7.99B | 43.3x | 0.24 | HK$8.06 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -40.2% Downside | Upgrade to Pro+ | |
Biocytogen Pharmaceuticals Beijing | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$7.91B | 154.7x | 1.87 | HK$18.98 | -4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -35.6% Downside | Upgrade to Pro+ | |
MiRXES Holding | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$7.62B | -5x | 0.32 | HK$29.10 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$6.51B | 166.6x | 1.94 | HK$10.26 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.7% Upside | Upgrade to Pro+ | |
ImmuneOnco Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$6.13B | -7x | -0.83 | HK$14.32 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CStone | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$5.86B | -34.5x | -0.82 | HK$4.69 | 8.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.1% Upside | Upgrade to Pro+ | |
Visen Pharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$5.49B | -21.9x | -1 | HK$47 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jacobio Pharmaceuticals Group | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.46B | -18.2x | -0.44 | HK$5.33 | -5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -61% Downside | Upgrade to Pro+ | |
Jiangsu Recbio Technology | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.95B | -6.3x | -3.16 | HK$8.30 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hua Medicine | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.25B | -11.9x | 0.67 | HK$3.28 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.7% Upside | Upgrade to Pro+ | |
Qyuns Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.16B | -6.9x | -0.24 | HK$14.78 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Antengene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.79B | -5.5x | -0.17 | HK$4.15 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -53.4% Downside | Upgrade to Pro+ | |
Frontage Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.31B | 370.5x | -4.23 | HK$1.31 | 14.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -10.1% Downside | Upgrade to Pro+ | |
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.02B | -13.9x | -0.38 | HK$0.50 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Immunotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.67B | -7.8x | -0.19 | HK$3.19 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tot Biopharm Intl | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.55B | 37x | 0.22 | HK$2.04 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.6% Upside | Upgrade to Pro+ | |
HighTide Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.42B | -2.1x | -0.04 | HK$2.76 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genor Biopharma Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.42B | -19.9x | -0.27 | HK$2.68 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Brii Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.40B | -2.6x | 0.01 | HK$1.95 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -47.5% Downside | Upgrade to Pro+ | |
Wuhan YZY Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$998.32M | -8.3x | -0.18 | HK$5.20 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jw Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$855.32M | -1x | -0.06 | HK$2.25 | 6.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
Sunho Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$816.61M | -6.7x | -0.17 | HK$5.46 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kintor Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$655.64M | -3.6x | -0.05 | HK$1.68 | 11.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sirnaomics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$438.24M | -0.6x | -0.03 | HK$4.14 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Clover Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$330.75M | -0.3x | 0 | HK$0.24 | -4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Health Inc | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$167.22M | -15.4x | -0.14 | HK$0.17 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Laekna | Hong Kong | Healthcare | Biotechnology & Medical Research | -0.5 | HK$22.15 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.8% Upside | Upgrade to Pro+ |